• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment.

作者信息

Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, Gelber R D, Goldhirsch A

机构信息

Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan.

Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan.

出版信息

Ann Oncol. 2019 Apr 1;30(4):653-655. doi: 10.1093/annonc/mdz034.

DOI:10.1093/annonc/mdz034
PMID:30698647
Abstract
摘要

相似文献

1
Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment.肿瘤突变负荷和肿瘤微环境的T细胞炎症的性别差异。
Ann Oncol. 2019 Apr 1;30(4):653-655. doi: 10.1093/annonc/mdz034.
2
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.识别和利用生物标志物预测免疫检查点抑制剂的反应。
AAPS J. 2020 Oct 14;22(6):132. doi: 10.1208/s12248-020-00514-4.
3
MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.可预测晚期黑色素瘤患者抗程序性死亡蛋白1（PD-1）疗法疗效的微小RNA
J Dermatol Sci. 2020 Jan;97(1):77-79. doi: 10.1016/j.jdermsci.2019.11.010. Epub 2019 Nov 30.
4
Firing Up Cold Tumors.激活冷肿瘤
Trends Cancer. 2019 Sep;5(9):528-530. doi: 10.1016/j.trecan.2019.06.005. Epub 2019 Jul 13.
5
In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.简而言之：帕博利珠单抗（可瑞达）用于治疗带有生物标志物的癌症。
Med Lett Drugs Ther. 2018 Jan 1;60(1537):e8.
6
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.T 细胞炎症基因表达谱、程序性死亡配体 1 表达和肿瘤突变负担可预测帕博利珠单抗治疗 20 种癌症患者的疗效：KEYNOTE-028。
J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.
7
Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab.肿瘤突变负荷：帕博利珠单抗临床获益的新预测指标。
Clin Cancer Res. 2024 Sep 3;30(17):3652-3654. doi: 10.1158/1078-0432.CCR-24-1261.
8
ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.ARID1A 缺失与免疫检查点阻断治疗：从机制到临床应用。
Cancer Lett. 2020 Mar 31;473:148-155. doi: 10.1016/j.canlet.2020.01.001. Epub 2020 Jan 3.
9
The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy.生物标志物在优化免疫肿瘤治疗中的价值。
Curr Drug Targets. 2019;20(1):81-86. doi: 10.2174/1389450119666180911093143.
10
Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.idelalisib增强CD37抗体BI 836826对化疗耐药/复发起始的慢性淋巴细胞白血病细胞的细胞毒性：联合治疗的理论依据
Blood Cancer J. 2016 Nov 11;6(11):e496. doi: 10.1038/bcj.2016.106.

引用本文的文献

1
Melanoma Tumor Mutational Burden and Indoor Tanning Exposure.黑色素瘤肿瘤突变负荷与室内晒黑暴露
JAMA Dermatol. 2025 Feb 1;161(2):198-202. doi: 10.1001/jamadermatol.2024.4819.
2
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications.免疫肿瘤学中性别偏见的特征：机制和治疗意义。
Nat Rev Cancer. 2024 May;24(5):338-355. doi: 10.1038/s41568-024-00680-z. Epub 2024 Apr 8.
3
LAG3 in gastric cancer: it's complicated.LAG3 在胃癌中的作用：错综复杂。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10797-10811. doi: 10.1007/s00432-023-04954-1. Epub 2023 Jun 14.
4
High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation.PD-L1 高表达主要发生于非小细胞肺癌患者中的鳞癌或低分化癌患者中。
Oncol Res. 2023 May 24;31(3):275-286. doi: 10.32604/or.2023.028227. eCollection 2023.
5
MicroRNAs modulate neuroinflammation after intracerebral hemorrhage: Prospects for new therapy.微小 RNA 调节脑出血后的神经炎症：新疗法的前景。
Front Immunol. 2022 Nov 1;13:945860. doi: 10.3389/fimmu.2022.945860. eCollection 2022.
6
Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis.非小细胞肺癌免疫治疗反应的性别差异：一项更新的荟萃分析。
Ann Med. 2022 Dec;54(1):2606-2616. doi: 10.1080/07853890.2022.2124449.
7
Sex-specific differences in immunogenomic features of response to immune checkpoint blockade.免疫检查点阻断反应的免疫基因组特征中的性别特异性差异。
Front Oncol. 2022 Aug 3;12:945798. doi: 10.3389/fonc.2022.945798. eCollection 2022.
8
Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review.非小细胞肺癌患者对靶向治疗和免疫治疗反应的性别差异：一项叙述性综述。
Transl Lung Cancer Res. 2022 May;11(5):920-934. doi: 10.21037/tlcr-21-1013.
9
Molecular Analysis in a Glioblastoma Cohort-Results of a Prospective Analysis.胶质母细胞瘤队列中的分子分析——一项前瞻性分析的结果
J Pers Med. 2022 Apr 26;12(5):685. doi: 10.3390/jpm12050685.
10
Sexual dimorphism in cancer: insights from transcriptional signatures in kidney tissue and renal cell carcinoma.癌症中的性别二态性：来自肾脏组织和肾细胞癌转录特征的见解。
Hum Mol Genet. 2021 Apr 27;30(5):343-355. doi: 10.1093/hmg/ddab031.